A STUB1–CHIC2 complex inhibits CD8<sup>+</sup> T cells to restrain tumor immunity – New Study
Nature Immunology, Published online: 12 August 2025; doi:10.1038/s41590-025-02231-6
LaFleur, Milling et al. perform an in vivo CRISPR screen of CD8+ T cells responding to tumors. They identify the E3 ubiquitin ligase STUB1 as a potent negative regulator of CD8+ T cell responses in tumors.
Summary
In a Nature Immunology study, LaFleur, Milling et al. utilized an in vivo CRISPR screen to analyze CD8+ T cells fighting tumors. Their research pinpointed STUB1, an E3 ubiquitin ligase, as a significant negative regulator of these crucial immune cells within the tumor microenvironment. This finding suggests that targeting STUB1 could potentially enhance CD8+ T cell activity and improve anti-tumor immune responses. The study highlights a novel therapeutic target for boosting the efficacy of cancer immunotherapy.
Read more…
Credits: Source
This post is part of “Science/Immunology News”, Follow for more…!!!
